SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

No debt, huge cashflow. One of the few US based companies with market penetration in China.

After the downfall in november ready to jump towards USD 7,50

The market blinked a little at SciClone's recent earnings, likely due to a downtick in revenues from recently acquired subsidiary NovaMed. I'm not sure what this signifies, although I have noticed a lot of cyclicity in revenues from pharmas based in China. What I do like about SciClone is that they've been solidly profitable for the last three quarters and they're using profits to build a stronger cash position. Since dilution seems to be a much more prevalent source of pipeline funding in the baby biotech sector, profitability always gets my attention. The remnants of SciClone's pipeline seem to have died out so a new acquisition is a substantial possiblity.

Sales keep growing year-to-year. China is a strong market for pharmaceuticals and this company is betting on it. I think they're doing the right thing. OUTPERFORM

This biotech, I mean volcano, is beginning to smoke. First I highly recommend doing YOUR OWN research, I can't express this enough. Do not base your decisions from what myself or some total stranger claims, which could be tainted with hidden motives and selfish pursuits. Being said, SCLN reminds me of an ex-girlfriend, an emotional roller coaster who rocked my world. With the new sales force and high projected sales, I see this babe reaching new heights. I also believe something is taking place behind closed curtains, which would explain the intense gain this week. Forget an American werewolf in London, here comes the American Biotech in China!!! Good luck to all! Rubi194@aol.com

low pe biotech

lowpricevaluestocks15

o This company is a biotech/drug company that is a small cap. It has buy and outperform analyst ratings, a P/E of 16.4x, its chart shows nice growth, and the technical analysis looks fairly bullish on this one. Also, this stock is beating all of its competitors in stock growth by about 100% and is starting to pull steadily above the S&P 500 growth. It has solid profitability, an extremely nice EPS growth rate of 241.5 (>98% of peers), and 25% internal ownership. Furthermore, with Obamacare, I am assuming SCLN will benefit from the healthcare bill. Earnings growth is the only thing that is not outstanding on this stock: it is steady growth but nothing extraordinary. I still like this one though.

Have been a stock holder and have been following this company for many years now. They've been through some very rough patches but finally seem to be on a solid steadily upward path. It's still risky and my position is small as Zadaxin had not really been shown to be an effective drug (so it's a mystery why China keeps buying it).

seriously this is just a guess do not follow my pick

SCLN is outperforming estimated earnings Q over Q lately. They have good exposure in China, one of the largest markets on the planet, and are reaching out into the international markets as well.

SciClone basically gets all their revenue from one product that isn't even approved for sale in the US, but is on sale in China! And sales grew 18% last year over 08, a rate of growth that seems to be increasing. Revenues for 09 over 08 grew a handsome 34%. The company has no debt.

Basically what we're looking at here is a pretty risky play. There's little doubt that their key drug will grow in sales, as will their revenue at an attractive rate, but should a piece of bad news come out about it, well, I wouldn't want to be caught holding shares.

That said, I think SCLN has room to run in the coming weeks, as news of their recent revenue ass-whooping is digested. Good luck with this one.

^Subida

low price prediction of income high

They have som experimental drugs in R and D that are very close to approval along with those already on the market makes this one a buy.

These guys have some great drugs in their pipeline. This is a cheap biotech to buy for the long term.

Putting a quality sells team in place in China to market it current product. This will allow them to expand on their already successful Zaxadin medication and they will be in place for their new products and could possibly market other newly approved meds.

good cancer trials

new managment is very capable of turning the comapany into a hidden gem.

China sales are up and melanoma trial results in Europe are due soon.